Xvivo Perfusion AB (publ) (LON:0RKL)

London flag London · Delayed Price · Currency is GBP · Price in SEK
176.05
+2.26 (1.30%)
At close: Sep 17, 2025
1.30%
Market Cap438.08M
Revenue (ttm)63.16M
Net Income (ttm)8.55M
Shares Outn/a
EPS (ttm)0.27
PE Ratio51.24
Forward PE59.18
Dividendn/a
Ex-Dividend Daten/a
Volume976
Average Volume14,741
Open176.20
Previous Close173.79
Day's Range176.00 - 176.60
52-Week Range163.60 - 524.00
Beta1.89
RSI44.51
Earnings DateOct 23, 2025

About Xvivo Perfusion AB

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermi... [Read more]

Industry Medical - Equipment & Services
Sector Healthcare
Founded 1998
Employees 190
Stock Exchange London Stock Exchange
Ticker Symbol 0RKL
Full Company Profile

Financial Performance

In 2024, Xvivo Perfusion AB's revenue was 822.42 million, an increase of 37.63% compared to the previous year's 597.54 million. Earnings were 172.18 million, an increase of 87.52%.

Financial numbers in SEK Financial Statements

News

Xvivo Perfusion AB (XVIPF) Q2 2025 Earnings Call Highlights: Navigating Challenges and Seizing ...

Xvivo Perfusion AB (XVIPF) Q2 2025 Earnings Call Highlights: Navigating Challenges and Seizing Growth Opportunities

2 months ago - GuruFocus

Q2 2025 Xvivo Perfusion AB Earnings Call Transcript

Q2 2025 Xvivo Perfusion AB Earnings Call Transcript

2 months ago - GuruFocus